Transarterial Chemoembolization for Hepatocellular Carcinoma: Why, When, How?

Area of Science:

• Hepatobiliary cancers
• Interventional oncology
• Gastroenterology

Background:

• Hepatocellular carcinoma (HCC) is the most frequent primary liver cancer, often linked to cirrhosis and chronic liver disease.
• Key risk factors include viral hepatitis (HBV, HCV), alcoholic liver disease (ALD), and non-alcoholic fatty liver disease (NAFLD).
• Treatment decisions for HCC depend on tumor stage, liver function, and patient health.

Purpose of the Study:

• To review the indications and optimal treatment schedules for transarterial chemoembolization (TACE) in HCC management.
• To evaluate technical factors influencing TACE efficacy.
• To assess the role of TACE as a personalized therapy for HCC.

Main Methods:

• Review of existing literature on transarterial chemoembolization (TACE) for hepatocellular carcinoma (HCC).
• Analysis of treatment indications, scheduling, and technical aspects of TACE.
• Evaluation of TACE outcomes in personalized HCC treatment strategies.

Main Results:

• Transarterial chemoembolization (TACE) is a primary treatment for intermediate-stage HCC.
• Optimal TACE application involves careful consideration of patient-specific factors and technical execution.

Conclusions:

• Transarterial chemoembolization (TACE) is a crucial, personalized treatment modality for intermediate-stage hepatocellular carcinoma (HCC).
• Further research into technical optimization and personalized scheduling can enhance TACE outcomes.